Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 08 February, 2007

XTL Biopharm Ltd

XTL to Present at the BIO CEO & Investor Co...


                   XTL Biopharmaceuticals to Present at the                    

                    9th Annual BIO CEO & Investor Conference                     

NEW YORK, NEW YORK, February 8, 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; 
LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, 
is scheduled to present at the 9th Annual BIO CEO & Investor Conference. Mr. Bentsur will present 
an overview of the Company including an overview of Bicifadine, the Company's recently in-licensed
late-stage clinical compound for the treatment of neuropathic pain. Mr. Bentsur's presentation will
take place on Wednesday, February 14th, 2007 at 3:00 pm Eastern Standard Time, at the Waldorf
Astoria Hotel in New York City.

A live audio webcast of Mr. Bentsur's presentation will be available at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=XTLB&item_id=1475520.
An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial
in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
combination of two monoclonal antibodies against the hepatitis C virus -
presently in Phase 1 clinical trials in patients with chronic hepatitis C.
XTL's hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecule inhibitors.  XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional drug
candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960

                                                                               
                                
                                                                               

                                                                                                                                                                            

a d v e r t i s e m e n t